Clinical trials: Viral Reactivation
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation
Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient
This study is a phase I, open-label study to determine recommended phase 2 dose (RP2D) for the BD03 vaccination in kidney transplant recipients.
- Conditions
- Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation, BK Virus Infection, Preventation of BK Virus Reactivation
- Trial name
- NCT03576014
- Testing
- BD03
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- SL VAXiGEN
Hepatocellular Carcinoma
Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study
Immune checkpoint inhibitor (ICI), including programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-Ligand 1 (PD-L1) inhibitor , is recommended to treat advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04680598
- Testing
- ICI, Antiviral Prophylaxis
- Where
- 4 sites in China
- Volunteers
- 800 people
- Sponsor
- Sun Yat-sen University
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs)
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant.
- Conditions
- Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
- Trial name
- VSTs (NCT02048332)
- Testing
- Viral specific VST Infusion
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Long COVID-19, Long COVID
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19…
- Trial name
- RECOVER-VITAL (NCT05965726)
- Testing
- Paxlovid, Ritonavir
- Where
- United States
- Volunteers
- 964 people
- Sponsor
- Kanecia Obie Zimmerman
Critical Illness
Cytomegalovirus Control in Critical Care
The purpose of this study is to determine whether reactivation of latent cytomegalovirus infection in critically ill patients looked after in the intensive care unit can be successfully and safely prevented using antiviral…
- Trial name
- CCCC (NCT01503918)
- Testing
- Valaciclovir/Aciclovir, Valganciclovir/Ganciclovir
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Efficacy of Elevated CD4 Counts on CMV Retinitis
Some patients with HIV/AIDS suffer from a dangerous viral infection of the retina (and other organs) called cytomegalovirus infection (CMV). The medications currently used to treat CMV all have serious side effects.
- Trial name
- NCT00091884
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Lymphoma, Chronic Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral…
- Trial name
- NCT02056548
- Volunteers
- 126 people
- Sponsor
- Seoul St. Mary's Hospital
Skin Cancer, Infection Reactivation
Viral Reactivation and Skin Cancer
Several studies show that the incidence of skin cancer parallels the length and depth of immunosuppression. This study will analyze the correlation of viral reactivation and skin cancer in organ transplant recipients.
- Trial name
- NCT02395562
- Where
- Switzerland
- Volunteers
- 1,200 people
- Sponsor
- University of Zurich
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01481649
- Where
- Hong Kong
- Volunteers
- 69 people
- Sponsor
- The University of Hong Kong
Hepatitis, Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients
This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma…
- Conditions
- Hepatitis, Hepatitis B, Lymphoma, Hematologic Diseases
- Trial name
- NCT02108444
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Peking University
Genital Herpes, HIV Infection
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1…
- Trial name
- NCT00527618
- Testing
- valacyclovir, acyclovir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
HBV Reactivation, HSCT
HBV Reactivation Prediction Model in Allo-HSCT
Hepatitis B virus (HBV) reactivation is a serious complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), particularly in patients with resolved HBV infection (HBsAg-negative, anti-HBc-positive).
- Trial name
- HBV-post HSCT (NCT07644026)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 300 people
- Sponsor
- Xiao Hui Zhang
EBV Infection After Allogenic HSCT
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell…
- Trial name
- NCT07693881
- Testing
- Rituximab (R)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Nanfang Hospital, Southern Medical University
NPC
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients
The purpose of this study is to investigate the EBV reactivation rate in post-radiation and remission NPC patients, evaluate the safety and tolerance of EGCG and analyze the observational correlation between EBV reactivation and…
- Trial name
- NPC (NCT01744587)
- Testing
- Epigallocatechin Gallate (EGCG)
- Where
- Taiwan
- Volunteers
- 353 people
- Sponsor
- National Health Research Institutes, Taiwan
Chronic Lymphocytic Leukemia
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
This observational retrospective study will enroll at least 158 patients affected by Chronic Lymphoid Leukemia (CLL) with previous HBV exposure (HBsAg negative, anti-HBc positive with or without anti-HBs) treated with Ibrutinib…
- Trial name
- LLC1618 (NCT03528941)
- Testing
- Lamivudine, No prophylaxis
- Where
- 23 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
HBV (Hepatitis B Virus), HIV Infection
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1
The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the…
- Trial name
- OBILART (NCT06728917)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
HIV Infection, Herpes Simplex
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness.
- Conditions
- HIV Infection, Herpes Simplex, Sexually Transmitted Diseases
- Trial name
- NCT00378976
- Testing
- valacyclovir
- Where
- Peru
- Volunteers
- 20 people
- Sponsor
- University of Washington
Chronic Hepatitis B, Rheumatoid Arthritis
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic rheumatic disease, especially rheumatoid arthritis
- Conditions
- Chronic Hepatitis B, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01694264
- Testing
- Entecavir
- Where
- 22 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Seoul National University Hospital